During the Rare Bone Disease Summit — which took place in December 2021 — key aspects were discussed and proposals to overcome the challenges and improve the lives of people living with RBDs were presented. This recently published article provides an overview of the key points from this meeting.

A new study is going to take place in the USA to collect the perspectives of adolescents and young adults with achondroplasia about medicine options and choices for achondroplasia.

Inês Alves, mother of a 10 years-old girl that has achondroplasia and founder of Beyond Achondroplasia, and ANDO Portugal (The National Association of Skeletal Dysplasias), is conducting a research study included in her PhD project dedicated to people over 18 years-old with achondroplasia.

The pharmaceutical company Pfizer has recently decided to discontinue development of the drug Recifercept for the treatment of achondroplasia. 

Last month Ascendis Pharma revealed results on the Phase 2 ACcomplisH Trial in children with achondroplasia aged 2-10, showing TransCon CNP's potential to meet patient and caregiver needs for a safe, effective, tolerable, and convenient treatment for this condition.

A research team at Baylor College of Medicine and Texas Children’s Hospital in the United States is conducting a research study that you may be eligible for!